Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab ACT-AXIS study

To assess the hypothesis if tocilizumab (TCZ) is effective on disease activity, and also its effect in fatigue and other clinical and psychological disease-related factors in patients with rheumatoid arthritis (RA) treated with TCZ. A 24-week, multicenter, prospective, observational study in patient...

Full description

Bibliographic Details
Authors: Corominas, H, Alegre, C, Narvaez, J, Fernandez-Cid, CM, Torrente-Segarra, V, Gomez, MR, Pan, FM, Morla, RM, Martinez, FJR, Gomez-Centeno, A, Ares, LL, Molina, RG, Gonzalez-Albo, SP, Dalmau-Carola, J, Perez-Garcia, C, Alvarez, CB, Ercole, L, Terrancle, MA
Format: article
Status:Published version
Publication Date:2019
Country:España
Institution:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repository:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p2985
Online Access:https://i3pt.portalinvestigacion.com/publicaciones/2985
Access Level:Open access
Keyword:clinical practice
fatigue
patient-reported outcomes
rheumatoid arthritis
tocilizumab
Description
Summary:To assess the hypothesis if tocilizumab (TCZ) is effective on disease activity, and also its effect in fatigue and other clinical and psychological disease-related factors in patients with rheumatoid arthritis (RA) treated with TCZ. A 24-week, multicenter, prospective, observational study in patients with moderate to severe RA receiving TCZ after failure or intolerance to disease-modifying antirheumatic drugs or tumor necrosis factor-alpha was conducted. Of the 122 patients included, 85 were evaluable for effectiveness (85% female, 51.9 +/- 12.5 years, disease duration 8.7 +/- 7.4 years). Mean change in C-reactive protein level from baseline to week 12 was -11.2 +/- 4.0 (P<.001). Mean Disease Activity Index score (DAS28) decreased from 5.5 +/- 1.0 at baseline to 2.7 +/- 1.3 (P<.001) at week 24. Mean change in Functional Assessment of Chronic Illness Therapy score was -5.4 +/- 11.2 points at week 24. Multiple regression analysis showed that the improvement in DAS28, sleep, and depression explained 56% and 47% of fatigue variance at week 12 and 24, respectively. Tocilizumab is effective in reducing disease activity and results in a clinically significant improvement in fatigue, pain, swollen joint count, morning stiffness, sleepiness, depression, and DAS28; the last 3 were specifically identified as factors explaining fatigue variance with the use of TCZ in RA patients.

Similar Items